Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...

Drug Delivery: Parenteral Route

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.

International journal of clinical oncology·2026

Same author

Nanoparticulate Immunoactive Complex for Local Chemoimmunotherapy: From Murine Models to Pilot Canine Study.

Cancer research communications·2026

Same author

Drug Delivery Systems for Resiquimod to Control Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same author

Phosphatidylserine blockade by dipicolylamine-zinc enhances chemoimmunotherapy of B16F10 melanoma.

Journal of pharmaceutical sciences·2025

Same author

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Cancer research communications·2025

Same author

Effective communication with JCR editors in the peer review process.

Journal of controlled release : official journal of the Controlled Release Society·2025

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

Drug delivery systems for intraperitoneal therapy.

Gaurav Bajaj¹, Yoon Yeo

¹Department of Industrial and Physical Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.

Pharmaceutical Research

|March 4, 2010

Summary

This summary is machine-generated.

Intraperitoneal (IP) drug delivery offers targeted cancer therapy in the peritoneal cavity but faces challenges. Advanced systems like nanoparticles and hydrogels aim to improve drug retention and efficacy for treating IP malignancies.

More Related Videos

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

Related Experiment Videos

Last Updated: Jun 15, 2026

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

Area of Science:

Oncology
Pharmacology
Biomedical Engineering

Background:

Peritoneal cavity disorders include adhesions and intraperitoneal (IP) malignancies.
IP drug delivery enhances regional therapy for these conditions by increasing drug concentration and half-life.
Current IP drug delivery faces challenges like premature drug clearance, lack of specificity, and poor tissue penetration.

Purpose of the Study:

To review current intraperitoneal drug delivery systems for peritoneal cavity disorders.
To discuss the challenges and future directions in IP drug delivery development.

Main Methods:

Literature review of clinically and experimentally used IP drug delivery systems.
Analysis of challenges associated with IP drug delivery, including drug clearance and penetration.

Main Results:

IP drug delivery is a promising approach for IP malignancies compared to systemic administration.
Micro/nanoparticles and hydrogel-based systems are explored to prolong drug residence time.
Significant challenges remain in optimizing IP drug delivery systems.

Conclusions:

IP drug delivery holds potential for treating peritoneal cavity disorders, particularly malignancies.
Overcoming challenges in drug retention, specificity, and penetration is crucial for future development.
Further research into advanced delivery systems is needed to improve therapeutic outcomes.